



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 47/48	A1	(11) International Publication Number: WO 98/35701 (43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/GB98/00461 (22) International Filing Date: 13 February 1998 (13.02.98) (30) Priority Data: 9703002.7 13 February 1997 (13.02.97) GB 9712090.1 10 June 1997 (10.06.97) GB (71) Applicant (for all designated States except US): THERAMARK LIMITED [GB/GB]; 90 Fetter Lane, London EC4A 1JP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BLAKE, David [GB/GB]; 52 Ormonde Terrace, London NW8 7LR (GB). NAUGHTON, Declan [IE/GB]; 7 Angel Cottages, Woodhatch Road, Reigate RH2 7LJ (GB). ADAMS, Ged [GB/GB]; 59 Ladder Hill, Wheatley, Oxford OX33 1HY (GB). STRATFORD, Ian [GB/GB]; Bretton Cottage, Bretton, Eyam, Sheffield S30 1HH (GB). MORRIS, Christopher [GB/GB]; 36 Boundary Road, Chippenham, Wiltshire SW15 3NN (GB). JAFFAR, Mohammed [GB/GB]; 12 Everett Court, Everett Road, Withington, Manchester M20 3DT (GB). NAYLOR, Matthew [GB/GB]; 16 The Firs, Hammondstreet Road, West Cheshunt, Hertfordshire EN7 6UD (GB).		(74) Agent: ATKINSON, Peter, Birch; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: <u>DRUG TARGETING</u> (57) Abstract <p>The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.</p>		